Drug intelligence / Profile preview

SYMB-104

Development stage: Preclinical
Lead developer: Symbiotix Biotherapies
Modality: Small Molecules
Administration: Intravenous

Overview

**SYMB-104** is a preclinical T-cell receptor (TCR) agonist developed by Symbiotix Biotherapies, Inc. It activates TCRs to modulate immune responses, primarily targeting inflammatory conditions such as inflammatory bowel diseases (IBD). As a novel immunotherapy, it aims to harness T-cell activity for therapeutic benefit in autoimmune and inflammatory disorders.[1][8]

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on SYMB-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYMB-104.

Explore the full profile